Number of eligible people: CDEC mentioned the uncertainty in the number of patients with reasonably critical to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some people that are categorized as getting moderate or reasonable condition may have a severe bleeding phenotype, https://buzzm205nkk3.wannawiki.com/user